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Abstract 
 
Background: One of the most widely used methods to detect tuberculosis (TB) infection is the tuberculin skin 
test (TST). The completion of Mycobacterium tuberculosis (M. tuberculosis) genome sequence has led to identi-
fication of several antigens that can be utilized for accurate diagnosis and control of TB. The aim of this study 
was to purify the recombinant M. tuberculosis antigens for the evaluation of their potential in TB diagnosis. 
 
Methods: The recombinant secretory antigens, ESAT-6, CFP-10 and ESAT-6/CFP-10 were produced by PCR 
and cloning methods. To investigate antigen specific responses of these recombinant antigens in detection of 
TB, ex vivo enzyme linked immunospot (ELISPOT) test in 30 clinically diagnosed TB patients was evaluated.  
 
Results: The selected M. tuberculosis antigens were cloned, expressed and purified in Escherichia coli (BL21). 
ELISPOT assay for detection of TB showed the sensitivity of 93, 90 and 100% for recombinant ESAT-6, CFP-10 
and ESAT-6/CFP-10 proteins respectively, which is significantly higher than conventional TST.  
 
Conclusion: The recombinant antigens of ESAT-6, CFP-10 and ESAT-6/CFP-10 can be used as an accurate 
means of detecting TB in Iran. 
 
Keywords: Mycobacterium tuberculosis; ELISPOT; CFP-10; ESAT-6; Tuberculosis; Diagnosis 
 
 
Introduction 
 
Despite more than a century of research on detection 
and treatment of Tuberculosis (TB) infection 
throughout the world, the disease remains a major 
cause of morbidity and mortality. TB accounts for 
approximately three million deaths annually with nine 
million new cases of the disease diagnosed each 
year.
1,2 In 2008, the World Health Organization 
(WHO) estimated that yearly about 1.7 million people 
die because of TB.
3 The incidence of all forms of TB 
in Eastern Mediterranean sub region countries such as 
Iran is 104 per 100000 and the incidence of cases 
which were smear positive is 24 per 100000 popula-
tions.
4 In Iran, most of the new TB cases occur among 
immigrants especially in Afghan immigrants. 
The major cause of TB is Mycobacterium tubercu-
losis (M. tuberculosis) which is an intracellular path-
ogen. Alveolar macrophages are the main target of 
invasion by M. tuberculosis bacilli that have the po-
tential to survive and grow in this cells.
5 Fast and ac-
curate diagnosis of TB is an important element in   
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controlling the disease. During the recent years, there 
has been emphasis on the development of new and 
rapid tests for the diagnosis of TB such as detection 
of M. tuberculosis components in clinical specimen 
using cell-mediated immune (CMI) responses.
6  
Tuberculin skin test (TST) with purified protein 
derivative (PPD) as one of the CMI-based tests in 
detection of TB infection has low specificity.
7 There-
fore, a new diagnostic test based on specific antigens 
would be of great value in screening and detection of 
TB. The availability of the completely sequenced ge-
nome of M. tuberculosis has provided tools for the 
identification of bacterial antigens that are useful in 
the development of new reagents to diagnose and 
control TB.
7 
Genome of M. tuberculosis consists of 16 regions 
of differences (RD). Among these regions, the RD1 
locus which plays a key role in the virulence of M. 
tuberculosis, is present in clinically pathogenic strains 
of M. tuberculosis and M. bovis, but is deleted in M. 
bovis BCG (bacillus Calmette-Guerin) vaccine 
strains.
4 This region contains nine protein coding 
genes (RV3871-3879c), which probably encodes pro-
tective and/or virulent antigens.
7,8  
Among the major antigens of RD1 locus, early se-
cretory antigenic target-6 (ESAT-6) and culture fil-
trate protein-10 (CFP-10) are encoded by the genes 
esxA and esxB respectively and form a 1:1 heterodi-
meric complex in vitro. ESAT-6 is the best-
characterized protein within the RD1 region. It has 
been recognized as an important stimulator of T-cells 
both in vitro and in vivo.
9 Also, it has been proposed 
as a tool for diagnosis of M. tuberculosis infection 
and frequently used in enzyme-linked immunospot 
assay (ELISPOT).
10,11 This assay is a specific method 
for identifying M. tuberculosis infection from the re-
sponse to BCG vaccination. It has based on produc-
tion of interferon gamma (IFN-γ by activated T cells 
after exposure to M. tuberculosis antigens.   
The CMI-based tests such as ELISPOT permit ear-
ly detection of TB infection in a setting of low ende-
micity and provide an inexpensive tool for diagnosis 
of TB in developing countries. Given the significance 
of ESAT-6 and CFP-10 secretion in mycobacterial 
virulence and the importance of these antigens as di-
agnostic tools for the detection of TB, we expressed 
and purified these two antigens as well as their fused 
form. In order to evaluate their validity for detection 
of TB patients, commercial ESAT-6 was used and its 
diagnostic potential compared with the produced re-
combinant proteins. 
Materials and Methods 
 
The study population (n=60) was divided into two 
groups: The first group (n=30) comprised of patients 
who were diagnosed with pulmonary TB (as con-
firmed by examination of sputum for acid-fast bacilli 
and/or culturing), with no history of treatment for the 
disease. Twenty percent of these patients were Af-
ghan immigrants and PPD skin test for all TB patients 
was performed. Twenty five percent of the patients 
had negative PPD skin test. All blood samples were 
obtained from the newly diagnosed sputum smear 
positive patients reported to the Masih Daneshvari 
Hospital in Tehran before administration of chemo-
therapy. The healthy BCG-vaccinated individuals 
(n=30) were group number 2. Healthy donors were 
individuals without prolonged direct contact with TB 
patients, with no vaccination during 10 years ago or 
any other clinical TB symptom. HIV positive indi-
viduals were excluded from the study. All the patients 
and normal subjects gave their written informed con-
sent prior to participation in the study. 
Mouse monoclonal ESAT-6 antibody and Glutathi-
one S Transferase (GST) antibody were obtained from 
Santa Cruz Biotechnology (Santa Cruz, CA) and 
mouse monoclonal CFP-10 antibody was purchased 
from Abcam; Glutathione agarose was purchased from 
Sigma and isopropyl-1-thio-β-D-galactopyranoside 
(IPTG) was obtained from Fermentas (USA). Com-
mercial ESAT-6 was obtained from Staten Serum In-
stitute (Copenhagen, Denmark). 
Purified DNA from different strains of Mycobac-
teria including Mycobacterium tuberculosis C ( M. 
tuberculosis C), Mycobacterium tuberculosis DT, 
Mycobacterium tuberculosis PN, Mycobacterium bo-
vis AN5 and Mycobacterium IR 150 were provided 
from Razi Serum and Vaccine Research Institute 
(Tehran, Iran). Using bioinformatic analysis, we 
compared the genome of these strains with M. tuber-
culosis H37RV. Native M. tuberculosis C strain, con-
sequently was selected for our analysis due to its ge-
nomic resemblance to H37RV. 
Standard procedures for PCR, transformation, 
cloning and analysis of DNA were used.
5-12 All con-
structs made by PCR were sequenced to verify their 
integrity. Esat-6, cfp-10 and esat-6/cfp-10 fusion 
genes were amplified from genomic DNA of M. tu-
berculosis C using the forward and reverse primers 
shown in Table 1. The PCR products were cloned 
into pGEX4T1 containing N-terminal GST tag. Re-
combinant plasmids were transformed to E. coli  Hemmati et al. 
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(DH5α). Positive clones were evaluated to find the 
correct insertion.  
Expression and purification of the recombinant pro-
teins were performed by standard protocols.
5,7 E. coli 
BL21 (DE3) transformed by pGEX4T1 (+) was grown 
in LB medium containing 100 µg/ml ampicillin. Ex-
pression was induced at mid-log phase by adding IPTG. 
Cell pellets were lyzed in lysis buffer comprises of 1% 
of Triton X-100, 1 mM EDTA (pH=8.0), aprotinin, 
leupeptin and pepstain A (1 µg/ml of each) in PBS. The 
cell lysates were sonicated, and the suspension was cen-
trifuged.
5 The mixture was allowed to bind to glutathi-
one agarose beads. The lysate-bead mixture was incu-
bated with reduced glutathione reagent to elute GST-
tagged proteins. After dialysis, purity of proteins was 
analyzed by SDS-PAGE and western blotting. For pro-
ducing pure recombinant proteins without GST-tag, 
thrombin cleavage of the proteins was performed. 
The SDS-PAGE of recombinant protein products 
was performed in the presence of 0.1% SDS in the 
gel. Protein samples (with and without GST) were 
prepared by mixing with reducing sample buffers
13 
and boiling in a sand bath for 5 minutes. Gel was run 
at a constant voltage of 200 V. Recombinant proteins 
transferred to nitrocellulose membranes (Millipore, Bi-
omanufacturing and Life Science Research) using mini 
Trans-blot Cell (Bio-Rad). The blots were incubated 
with an appropriate dilutions of primary anti-ESAT-6, 
anti-CFP-10 and anti-GST antibodies and then were 
incubated with horseradish peroxidase-conjugated sec-
ondary antibody solution. Finally blots were processed 
using Enhanced chemiluminescence (ECL).
5  
The Far-UV CD spectra were used to determine 
the secondary structure of the recombinant proteins in 
an Avir circular dichroism spectropolarimeter model 
215. Protein samples were dissolved in buffer 50 mM 
Tris-HCl pH 8.0, 180 mM NaCl, 1 mM Dithiothreitol 
(DTT) and 10% v/v glycerol. CD Spectra of the pro-
teins were recorded from 190 to 260 nm, each spec-
trum representing an average of 3 accumulations. 
Interferon gamma ELISPOT assay for detection and 
enumeration of IFN-γ producing T-cells against myco-
bacterial antigens was performed by using a commer-
cially available anti IFN-γ antibody pair and black spot 
developing reagents from U-Cytech (U-CyTech, Neth-
erland).
11,12 Briefly, peripheral blood mononuclear cells 
(PBMCs) (2×10
5 cells/well) were added to duplicate 
wells pre-coated with anti- IFN-γ antibody. Following 
the overnight stimulation with ESAT-6, CFP-10, ESAT-
6/CFP-10, commercial ESAT-6 and PPD, plain medium 
(as negative control), and phytohemagglutinin (PHA, as 
positive control), the wells were washed, and the pres-
ence of IFN-γ was detected by biotinylated anti-IFN-γ 
and φ-labeled goat anti-biotin antibody. Afterward addi-
tion of activators I and II precipitated silver on φ and 
revealed the spots of IFN-γ secreting cells. The spots 
were enumerated with a stereomicroscope and photo-
graphed digitally. The number of spots in the back 
ground control wells was subtracted from the number in 
the test wells and a response was considered positive if 
the number of spots per test well was greater than the 
cutoff point for each antigen and at least twice the value 
found in the background control wells. The means of the 
duplicates were used and all results were expressed as 
number of IFN-γ spot-forming cells (SFC) per million 
PBMC for comparison.
14,15 
The statistical significance of differences between 
experimental and control groups were determined by 
Mann-Whitney U test (SPSS software, version 16.0, 
Chicago, IL, USA). Data were considered statistically 
significant at p<0.05. For evaluation of antigen re-
sponses, cutoff values were calculated for each   
Table 1: Primers and vector used for cloning of esat-6, cfp-10 and esat-6/cfp-10
a 
Antigen                  Primer sequence( 5
'  to  3
' )                              Forward (F)          Cloned between         Vector
                                                                                                           or 
                                                                                                           Reverse (R)                                              
ESAT-6               TAAGGATCCATGACAGAGCAGGAGTG              F                          BamHI and ECORI     pGEX4T1 
                            GCGAATTCTGCGAACATCCCAGTG                   R                                                                              
CFP-10               TAAGGATCCATGGCAGAGATGAAGAAC            F                          BamHI and ECORI     pGEX4T1 
                            GCGAATTCGAAGCCCATTTGCGAGGA              R                        
                            TAAGGATCCATGACAGAGCAGGAGTG
                F                          BamHI                        pGEX4T1 
ESAT-6/CFP-10  GGAACCTGGAGATGCGAACATCCCAGTG        R                                                                           
 
                            TCTCCAGGTTCCATGGCAGAGATGAAGAAC
      F
  
                            AAGGAATTCGAAGCC CATTTGCGAGGA
            R                          ECORI                       pGEX4T1 
GGATCC : BamHI site,   GAATTC :ECORI site 
GGAACCTGGAGA: Linker      TCTCCAGGTTCC: linker 
a Restriction sites are underlined. Recombinant antigens in diagnosis of TB 
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antigen as the means of spot forming cells + two 
standard deviation (SD) obtained with the PBMCs 
from 30 healthy BCG-vaccinated donors. 
 
 
Results 
 
In this study, we amplified esat-6, cfp-10 and esat-
6/cfp-10 fusion genes from native M. tuberculosis C 
genomic DNA by PCR. All PCR products, 288 bp for 
esat-6, 303 bp for cfp-10 and 591 bp for esat6/cfp10 
were cloned into pGEX4T1 expression vector. DNA 
sequencing of the genes showed that all cloned genes 
were identical to genes reported on gene bank (esat-6, 
Accession Nos.RV3875; cfp-10, Accession Nos. 
Rv3874). Esat-6 and cfp-10 genes were completely 
inserted in the fusion gene.  
The recombinant proteins were all purified from 
cell-free supernatants by affinity chromatography on 
GST-Agarose. The expressed products were subject-
ed to SDS-PAGE using mini format vertical electro-
phoresis (BIO-RAD, USA). Gels were run in tricine-
tris running buffer. Expression and purification re-
sults for ESAT-6, CFP-10 and ESAT6/CFP10 pro-
teins were shown in Figure 1. The theoretical molecu-
lar weight of pure ESAT-6, CFP-10, and ESAT-
6/CFP-10 is about 10, 13 and 25 KDa, respectively in 
E. coli expression system. The resolved proteins were 
transferred to nitrocellulose membrane to identify 
expression, by western immunoblotting using mini 
trans–blot cell (Bio-Rad, USA). ESAT-6/CFP-10 fu-
sion protein could be recognized by mouse anti GST, 
anti ESAT-6 and anti-CFP-10 monoclonal antibodies. 
Western blot results were shown in Figure 2.  
 
Fig. 1: Expression and purification of ESAT-6, CFP-10 and ESAT-6/CFP-10 proteins. Samples (Lane 1-6) were 
resolved in a 16% (w/v) polyacrylamide gel, under reducing conditions. 1) Un-induced cell; 2) induced cell; 3) glu-
tathione-agarose flow through (unbound); 4) washed glutathione agarose showing bound protein; 5) thrombin 
cleaved supernatant; 6) washed glutathione agarose after thrombin cleavage. Molecular weight standards are 
shown to the left of lane 1. 
 
 
Fig. 2: Western blots of ESAT-6/CFP-10 fusion protein probed with mouse anti-GST (A), mouse anti-ESAT-6 (B), 
and mouse anti-CFP-10 (C) monoclonal antibodies. Lanes1and 2 represent ESAT-6/CFP-10 protein with and 
without thrombin cleavage. Hemmati et al. 
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The structural states of the recombinant proteins 
were confirmed by CD spectroscopy. As shown in 
Figure 3, both ESAT-6 and ESAT-6/CFP-10 have 
high helical contents, whereas CFP-10 appears to 
have largely unstructured, random coil structure. 
 
 
Fig. 3:  Far-UV circular dichroism  spectra obtained 
from solution of CFP-10 (A), ESAT-6 (B), and ESAT-
6/CFP-10 (C). 
 
The samples from healthy individuals were ana-
lyzed to calculate mean and standard deviation (SD) 
and then cutoff point for positive samples was set at 
mean + 2SD.
6 The distribution of responses to ESAT-
6, CFP-10, ESAT-6/CFP-10, PPD and commercial 
ESAT-6 was shown in Figure 4. Results are mean 
values determined by independent observers, given as 
spots per million PBMCs. Numbers of IFN-γ  SFC 
against ESAT-6, CFP-10 , ESAT-6/CFP-10 and 
commercial ESAT-6 were significantly higher in TB 
patients than in BCG-vaccinated healthy donors (Fig-
ure 4). All patients participated in this study were 
previously vaccinated with BCG, nevertheless 25% of 
them showed negative skin test. All the patients in 
our IFN-γ ELISPOT analysis for ESAT-6, CFP-10 
ESAT-6/CFP-10 and commercial ESAT-6, showed 
positive reaction. Sensitivity, specificity, positive 
predictive value (PPV) and negative predictive value 
(NPV) for recombinant proteins and PPD in 
ELISPOT assay were summarized in Table 2.  
 
 
Discussion 
 
Late diagnosis and treatment of tuberculosis increases 
the risk of disease dissemination and decreases the 
survival of some subgroups of patients.
16-18 Thus new 
advancements in techniques, which facilitate rapid 
diagnosis, are required to control TB successfully. 
Using ESAT-6 and CFP-10, two specific antigens 
encoded in the RD1 locus of the bacterial genome, 
which distinguish M. tuberculosis from other Myco-
bacteria, has increased specificity and sensitivity of 
IFN-γ ELISPOT assay.
14 This study reports the re-
sults of the first evaluation of ex vivo INF-γ based 
assay (TSPOTTB) for the diagnosis of TB in adults 
by recombinant antigens of native M. tuberculosis C 
as the standard strain of Iran. The antigens chosen for 
the present study have been found to be strong targets 
for human B- and T-cell responses.
19 Overlapping 
peptides of ESAT-6 and CFP-10 offer increased spec-
ificity over the PPD skin test when they were used in 
ELISPOT assay for the diagnosis of M. tuberculo-
sis.
20,21 Arend et al. have shown that ESAT-6 and 
CFP-10 in combination with T-cell assays can pro-
vide the level of specificity and sensitivity necessary 
to detect exposure to TB.
22 According to our results 
from ELISPOT assay, these recombinant proteins 
could discriminate TB patients from healthy BCG-
vaccinated individuals with p values <0.001. Accord-
ing to values of sensitivity, specificity, PPV and NPV 
for all recombinant produced proteins, commercial 
ESAT-6 and PPD, and considering that 25% of TB 
patients were negative in their TST result, we suggest 
that ESAT-6 and ESAT-6/CFP-10 proteins could 
provide high level of confidence for application in 
Table 2: Values of sensitivity, specificity, PPV and NPV
Antigens Sensitivity Specificity PPV NPV 
Recombinant  ESAT-6  93  100 100 100 
Recombinant CFP-10  90  96  96  100 
Recombinant  ESAT-6/CFP-10  100  100 100 100 
Commercial  ESAT-6  93  100 100 100 
PPD 76  85  90  80 Recombinant antigens in diagnosis of TB 
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diagnosis of TB. Our results indicated higher sensitiv-
ity and specificity of fusion protein and poor sensitiv-
ity of PPD in the diagnosis of TB patients which is in 
agreement with other findings.
6,8,20,22 These recombi-
nant proteins offer a realistic and cost effective alter-
native to PPD and their availability in pure form will 
facilitate this application. In conclusion, we cloned, 
expressed and purified large amounts of recombinant 
secretory antigens ESAT-6, CFP-10 and ESAT-
6/CFP-10. These proteins were purified easily by af-
finity chromatography and checked with western 
blotting and circular dichroism methods.  
Due to higher sensitivity and specificity, recombi-
nant antigens ESAT-6, CFP-10 and ESAT-6/CFP-10 
can be better candidates for detection of TB when 
compared with conventional diagnostic methods such 
as PPD skin test. Since there was a high similarity in 
sensitivity of ELISPOT test between commercial 
 
 
Fig. 4: Frequency of IFN-γ SFCs in a million of PBMCs responding to recombinant proteins in different individual 
groups. A dotted horizontal line is included to show the cutoff value for a positive response for ESAT-6/CFP-10 (A), 
ESAT-6 (B), CFP-0 (C), commercial ESAT-6 (D), and PPD (E). 
 Hemmati et al. 
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ESAT-6 (a worldwide standard means of TB detec-
tion) and produced recombinant proteins, these re-
combinant antigens can be a reliable diagnostic tool 
for detection of TB. 
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